Compare FNB & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNB | GKOS |
|---|---|---|
| Founded | 1864 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.0B |
| IPO Year | 2001 | 2015 |
| Metric | FNB | GKOS |
|---|---|---|
| Price | $16.17 | $103.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $19.10 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 7.9M | 591.7K |
| Earning Date | 04-15-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 22.83 | N/A |
| EPS | ★ 1.56 | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $14.53 | $23.34 |
| Revenue Next Year | $7.90 | $27.46 |
| P/E Ratio | $10.59 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $10.93 | $73.16 |
| 52 Week High | $19.14 | $130.23 |
| Indicator | FNB | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 40.54 | 44.08 |
| Support Level | $15.81 | $94.92 |
| Resistance Level | $16.27 | $104.66 |
| Average True Range (ATR) | 0.36 | 4.03 |
| MACD | 0.07 | 0.64 |
| Stochastic Oscillator | 50.00 | 54.14 |
F N B Corp provides a full range of financial services, principally to consumers, corporations, governments, and small- to medium-sized businesses. It has three reportable business segments: Community Banking, Wealth Management, and Insurance. The majority of revenue is from the Community banking segment. It offers commercial & consumer banking services. Commercial banking solutions include corporate banking, small business banking, investment real estate financing, business credit, capital markets & lease financing. Consumer banking products & services include deposit products, mortgage lending, & consumer lending & a complete suite of mobile & online banking services.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.